Return to Today's science sparks archives

2017-04-03

Fig 3. ProteoModlR computes exact and approximate abundance and PTM stoichiometry based on the available set of peptides for a given protein.

Fig 3. ProteoModlR computes exact and approximate abundance and PTM stoichiometry based on the available set of peptides for a given protein.
  • Cifani P, Shakiba M, Chhangawala S, Kentsis A

  • BMC Bioinformatics. 2017 Mar 4;18(1):153.
Open Access button

2017-04-04

Fig 2. PTEN expression in primary OCCCs.

Fig 2. PTEN expression in primary OCCCs.
  • Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS

  • Oncotarget. 2017 Jan 24;8(4):6057-6066.

2017-04-05

Fig 1. Histologic image of a hairy cell.

Fig 1. Histologic image of a hairy cell.
  • Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M

  • Blood. 2017 Feb 2;129(5):553-560.

2017-04-06

Fig 1. Intestinal damage and dysbiosis linked to GVHD.

Fig 1. Intestinal damage and dysbiosis linked to GVHD.
  • Staffas A, Burgos da Silva M, van den Brink MR

  • Blood. 2017 Feb 23;129(8):927-933.

2017-04-07

Fig 2. SmD2 and SmD1 structures and contacts with U4 snRNA.

Fig 2. SmD2 and SmD1 structures and contacts with U4 snRNA.
  • Schwer B, Roth AJ, Shuman S

  • RNA. 2017 Mar;23(3):420-430.

2017-04-10

Fig 2. Heat map showing hierarchical clustering analysis of the gene expression profiles of the ClearCode34 genes in metastatic renal cell carcinoma TCGA tumors (n = 54).

Fig 2. Heat map showing hierarchical clustering analysis of the gene expression profiles of the ClearCode34 genes in metastatic renal cell carcinoma TCGA tumors (n = 54).
  • de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Rathmell WK, Albiges L

  • Oncologist. 2017 Mar;22(3):286-292.

2017-04-11

Fig 1. TIRR is a novel partner of 53BP1.

Fig 1. TIRR is a novel partner of 53BP1.
  • Drané P, Brault ME, Cui G, Meghani K, Chaubey S, Detappe A, Parnandi N, He Y, Zheng XF, Botuyan MV, Kalousi A

  • Nature. 2017 Mar 9;543(7644):211-216.

2017-04-12

Fig 6. Vhl and Pbrm1 Doubly Deficient Clear Cell Kidney Tumors Display Hyperactive mTORC1 Signaling.

Fig 6. Vhl and Pbrm1 Doubly Deficient Clear Cell Kidney Tumors Display Hyperactive mTORC1 Signaling.
  • Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, Ray CE

  • Cell Rep. 2017 Mar 21;18(12):2893-2906.
Open Access button

2017-04-13

Fig 5. PD-1 expression among case and control patients displayed as heatmap.

Fig 5. PD-1 expression among case and control patients displayed as heatmap.
  • Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N

  • Blood. 2017 Mar 9;129(10):1380-1388.

2017-04-14

Fig 1. Venetoclax induces response in several non-Hodgkin lymphoma histologies.

Fig 1. Venetoclax induces response in several non-Hodgkin lymphoma histologies.
  • Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdungo, M, Humerickhouse RA, Gordon GB, Gerecitano JF

  • J Clin Oncol. 2017 Mar 10;35(8):826-833.

2017-04-17

Fig 1. The stepwise activation of ERK signaling results in the transcriptional activation of genes responsible for cell-cycle progression and feedback regulation.

Fig 1. The stepwise activation of ERK signaling results in the transcriptional activation of genes responsible for cell-cycle progression and feedback regulation.
  • Xue Y, Lito P

  • Clin Cancer Res. 2017 Mar 15;23(6):1365-1367.

2017-04-18

Fig 2. BCAP is expressed within BM HSPCs.

Fig 2. BCAP is expressed within BM HSPCs.
  • Duggan JM, Buechler MB, Olson RM, Hohl TM, Hamerman JA

  • Blood. 2017 Mar 16;129(11):1503-1513.

2017-04-19

Fig 1. The four basic morphologic features to diagnose tumors of follicular cell derivation: (i) papillary growth pattern; (ii) follicular growth pattern; (iii) presence of a tumor capsule and of its invasion, in the form of capsular or vascular invasion; (iv) alterations of nuclear morphology typical of papillary carcinoma.

Fig 1. The four basic morphologic features to diagnose tumors of follicular cell derivation: (i) papillary growth pattern; (ii) follicular growth pattern; (iii) presence of a tumor capsule and of its invasion, in the form of capsular or vascular invasion; (iv) alterations of nuclear morphology typical of papillary carcinoma.
  • Xu B, Tallini G, Ghossein RA

  • Endocr Pathol. 2017 Mar 30.

2017-04-21

Fig 3. Kaplan-Meier analysis comparing overall survival in patients treated with upfront stereotactic radiosurgery (SRS), upfront whole-brain radiotherapy (WBRT), and upfront epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), stratified by disease specific Graded Prognostic Assessment (GPA).

Fig 3. Kaplan-Meier analysis comparing overall survival in patients treated with upfront stereotactic radiosurgery (SRS), upfront whole-brain radiotherapy (WBRT), and upfront epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), stratified by disease specific Graded Prognostic Assessment (GPA).
  • Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR

  • J Clin Oncol. 2017 Apr 1;35(10):1070-1077.

2017-04-24

Fig 1. PLB labeling schemes.

Fig 1. PLB labeling schemes.
  • Fried ES, Li YM, Gilchrist ML

  • Langmuir. 2017 Mar 28;33(12):3028-3039.

2017-04-25

Fig 2. Differences in response assessment depending on the number of lesions analyzed.

Fig 2. Differences in response assessment depending on the number of lesions analyzed.
  • Pinker K, Riedl C, Weber WA

  • Eur J Nucl Med Mol Imaging. 2017 Mar 30.

2017-04-26

Fig 10. Patient induced susceptibility distortions in the MRCAT source MR images.

Fig 10. Patient induced susceptibility distortions in the MRCAT source MR images.
  • Tyagi N, Fontenla S, Zhang J, Cloutier M, Kadbi M, Mechalakos J, Zelefsky M, Deasy J, Hunt M

  • Phys Med Biol. 2017 Apr 21;62(8):2961-2975.

2017-04-27

Fig 1. Characterization of mutations, copy number, clinical data, and survival in HSTL cases.

Fig 1. Characterization of mutations, copy number, clinical data, and survival in HSTL cases.
  • McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T

  • Cancer Discov. 2017 Apr;7(4):369-379.

2017-04-28

Fig 9. Resected scapula after tumor recurred, cut in the coronal plane.

Fig 9. Resected scapula after tumor recurred, cut in the coronal plane.
  • Morris CD, Hameed MR, Agaram NP, Hwang S

  • Skeletal Radiol. 2017 Apr 10.

2017-05-01

Fig 8. Model summarizing the trafficking defects in Mks1krc/krc mutants as well as double mutants with Bbs and Ift.

Fig 8. Model summarizing the trafficking defects in Mks1krc/krc mutants as well as double mutants with Bbs and Ift.
  • Goetz SC, Bangs F, Barrington CL, Katsanis N, Anderson KV

  • PLoS One. 2017 Mar 14;12(3):e0173399.
Open Access button

2017-05-02

Fig 2. Actual and intended use of screening in BSD users.

Fig 2. Actual and intended use of screening in BSD users.
  • Elkin EB, Pocus VH, Mushlin AI, Cigler T, Atoria CL, Polaneczky MM

  • BMC Med Inform Decis Mak. 2017 Mar 21;17(1):29.
Open Access button

2017-05-03

Fig 2. Consensus somatic SVs and CNVs.

Fig 2. Consensus somatic SVs and CNVs.
  • Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, Craig DW, Adkins J, Cuyugan L, Manojlovic Z, Halperin RF, Helland A, Nasser S, Legendre C, Hurley LH, Sivaprakasam K, Johnson DB, Crandall H, Busam KJ, Zismann V, Deluca V, Lee J, Sekulic A, Ariyan CE, Sosman J, Trent J

  • Genome Res. 2017 Apr;27(4):524-532.

2017-05-04

Fig 3. A 70‐year‐old patient with metastatic breast cancer who developed an asymptomatic atypical femoral fracture (AFF) following classic prodromal symptoms and who also developed an atypical stress reaction on the contralateral femur.

Fig 3. A 70‐year‐old patient with metastatic breast cancer who developed an asymptomatic atypical femoral fracture (AFF) following classic prodromal symptoms and who also developed an atypical stress reaction on the contralateral femur.
  • Yang SP, Kim TW, Boland PJ, Farooki A

  • Oncologist. 2017 Apr;22(4):438-444.

2017-05-05

Fig 5. Gene expression changes in Tailor and Dis3L2 single and double mutants.

Fig 5. Gene expression changes in Tailor and Dis3L2 single and double mutants.
  • Lin CJ, Wen J, Bejarano F, Hu F, Bortolamiol-Becet D, Kan L, Sanfilippo P, Kondo S, Lai EC

  • RNA. 2017 Mar;23(3):284-296.

2017-05-08

Fig 1. Characterization of the SN-38-loaded unmodified and antibody-modified NPs, as determined by DLS and HR-SEM.

Fig 1. Characterization of the SN-38-loaded unmodified and antibody-modified NPs, as determined by DLS and HR-SEM.
  • Monterrubio C1, Paco S1, Olaciregui NG1, Pascual-Pasto G1, Vila-Ubach M, Cuadrado-Vilanova M, Ferrandiz MM, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, Sosnik A, Carcaboso AM

  • J Control Release. 2017 Apr 12;255:108-119.

2017-05-09

Fig 4. IFT54 co-localizes with microtubular structures during cell division.

Fig 4. IFT54 co-localizes with microtubular structures during cell division.
  • Zhu X, Liang Y, Gao F, Pan J

  • Cell Mol Life Sci. 2017 Apr 17.

2017-05-10

Fig 5. (A) Anion exchange chromatography profile of induced culture supernatant on a HiTrap Q Sepharose XL column. Elution was done in a linear gradient from 0 to 190 mM NaCl using 20 mM Tris-Cl/1 M NaCl pH 8. (B) Silver-stained SDS-PAGE shows fractions 1–12 (numbered lanes).

Fig 5. (A) Anion exchange chromatography profile of induced culture supernatant on a HiTrap Q Sepharose XL column. Elution was done in a linear gradient from 0 to 190 mM NaCl using 20 mM Tris-Cl/1 M NaCl pH 8. (B) Silver-stained SDS-PAGE shows fractions 1–12 (numbered lanes).
  • Damasceno L, Ritter G, Batt CA

  • Protein Expr Purif. 2017 Apr 5;134:72-81.

2017-05-11

Fig 2. MAVS signaling in nonhematopoietic cells maintains intestinal barrier function.

Fig 2. MAVS signaling in nonhematopoietic cells maintains intestinal barrier function.
  • Fischer JC, Bscheider M, Eisenkolb G, Lin CC, Wintges A, Otten V, Lindemans CA, Heidegger S, Rudelius M, Monette S, Rodriguez KA

  • Sci Transl Med. 2017 Apr 19;9(386).

2017-05-15

Fig 4. Model for proposed mechanism of nanoprobe translocation to the nucleus.

Fig 4. Model for proposed mechanism of nanoprobe translocation to the nucleus.
  • Budhathoki-Uprety J, Langenbacher RE, Jena PV, Roxbury D, Heller DA

  • ACS Nano. 2017 Apr 25;11(4):3875-3882.

2017-05-16

Fig 1. Structure of chimeric antigen receptors (CAR).

Fig 1. Structure of chimeric antigen receptors (CAR).
  • Hoseini SS, Cheung NV

  • Cancer Lett. 2017 Apr 17;399:44-52.

2017-05-17

Fig 6. Interphase fluorescent in situ hybridization detection of NTRK3 gene rearrangement.

Fig 6. Interphase fluorescent in situ hybridization detection of NTRK3 gene rearrangement.
  • Wang L, Busam KJ, Benayed R, Cimera R, Wang J, Denley R, Rao M, Aryeequaye R, Mullaney K, Cao L, Ladanyi M, Hameed M.

  • J Mol Diagn. 2017 May;19(3):387-396.

2017-05-18

Fig 2. Immune checkpoint inhibitors: releasing the brakes on the immune system. MHC, major histocompatibility complex; PD-1, programmed death 1; PD-L1, programmed death ligand-1; TCR, T-cell receptor.

Fig 2. Immune checkpoint inhibitors: releasing the brakes on the immune system. MHC, major histocompatibility complex; PD-1, programmed death 1; PD-L1, programmed death ligand-1; TCR, T-cell receptor.
  • Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS

  • J Clin Oncol. 2017 Apr 20;35(12):1341-1367.

2017-05-19

Fig 1. Algorithm for detection of mismatch repair deficiency in colorectal cancer.

Fig 1. Algorithm for detection of mismatch repair deficiency in colorectal cancer.
  • Hechtman JF, Middha S, Stadler ZK, Zehir A, Berger MF, Vakiani E, Weiser MR, Ladanyi M, Saltz LB, Klimstra DS, Shia J

  • Fam Cancer. 2017 Apr 12.

2017-05-22

Fig 1. Convergent Extension of the Ventral Nerve Cord.

Fig 1. Convergent Extension of the Ventral Nerve Cord.
  • Shah PK, Tanner MR, Kovacevic I, Rankin A, Marshall TE, Noblett N, Tran NN, Roenspies T, Hung J, Chen Z, Slatculescu C

  • Dev Cell. 2017 Apr 24;41(2):195-203.e3.

2017-05-23

Fig 1. High-level comparison of target enrichment workflow for amplicon and capture hybridization NGS assays.

Fig 1. High-level comparison of target enrichment workflow for amplicon and capture hybridization NGS assays.
  • Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, Temple-Smolkin RL, Voelkerding KV, Nikiforova MN

  • J Mol Diagn. 2017 May;19(3):341-365.

2017-05-24

Fig 4. Model for proposed mechanism of nanoprobe translocation to the nucleus.

Fig 4. Model for proposed mechanism of nanoprobe translocation to the nucleus.
  • Budhathoki-Uprety J, Langenbacher RE, Jena PV, Roxbury D, Heller DA

  • ACS Nano. 2017 Apr 25;11(4):3875-3882.

2017-05-25

Fig 3. Top alignments to full-length L1 loci from HEK293 cells.

Fig 3. Top alignments to full-length L1 loci from HEK293 cells.
  • Deininger P, Morales ME, White TB, Baddoo M, Hedges DJ, Servant G, Srivastav S, Smither ME, Concha M, DeHaro DL, Flemington EK, Belancio VP

  • Nucleic Acids Res. 2017 Mar 17;45(5):e31.
Open Access button

2017-05-26

Fig 1. The EML4–ALK rearrangement and downstream signaling.

Fig 1. The EML4–ALK rearrangement and downstream signaling.
  • Sabari JK, Santini FC, Schram AM, Bergagnini I, Chen R, Mrad C, Lai WV, Arbour KC, Drilon A

  • Onco Targets Ther. 2017 Apr 6;10:1983-1992.
Open Access button

2017-05-30

Fig 1. Examples of challenging diagnostic features of oncocytic renal cell neoplasms.

Fig 1. Examples of challenging diagnostic features of oncocytic renal cell neoplasms.
  • Williamson SR, Gadde R, Trpkov K, Hirsch MS, Srigley JR, Reuter VE, Cheng L, Priya Kunju L, Barod R, Rogers CG, Delahunt B, Hes O, Eble JN, Zhou M, McKenney JK, Martignoni G, Fleming S, Grignon DJ, Moch H, Gupta NS

  • Human Pathology. 2017 May 31;63:149-56.

2017-05-31

Fig 5. Frequencies of CD8+, CD4+, and TAM Clusters for Each ccRCC Sample.

Fig 5. Frequencies of CD8+, CD4+, and TAM Clusters for Each ccRCC Sample.
  • Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe'er D, Bodenmiller B

  • Cell. 2017 May 4;169(4):736-749.e18.
Open Access button

2017-06-01

Fig 2. Requirement of RNA splicing factor mutations in disease initiation vs maintenance.

Fig 2. Requirement of RNA splicing factor mutations in disease initiation vs maintenance.
  • Joshi P, Halene S, Abdel-Wahab O

  • Blood. 2017 May 4;129(18):2465-2470.

2017-06-02

Fig 2. Onset of diagnosis of neurologic morbidity compared with onset of subsequent meningiomas among childhood cancer survivors exposed to cranial radiation.

Fig 2. Onset of diagnosis of neurologic morbidity compared with onset of subsequent meningiomas among childhood cancer survivors exposed to cranial radiation.
  • Bowers DC, Moskowitz CS, Chou JF, Mazewski CM, Neglia JP, Armstrong GT, Leisenring WM, Robison LL, Oeffinger KC

  • J Clin Oncol. 2017 May 10;35(14):1570-1576.

2017-06-05

Fig 2. Representative slices of the proton therapy plan for the patient with a mean liver dose of 22 Gy and with 1,100 cm3 of the liver receiving <25 Gy.

Fig 2. Representative slices of the proton therapy plan for the patient with a mean liver dose of 22 Gy and with 1,100 cm3 of the liver receiving <25 Gy.
  • Colbert LE, Cloyd JM, Koay EJ, Crane CH, Vauthey JN

  • Surgery. 2017 Jun;161(6):1543-1548.

2017-06-06

Fig 2. Relative precision of a domain score by number of items.

Fig 2. Relative precision of a domain score by number of items.
  • Vickers AJ, Chen LY

  • Health Qual Life Outcomes. 2017 Apr 26;15(1):83.
Open Access button

2017-06-07

Fig 6. Administration of a Four-Bacteria Consortium Clears VRE from Densely Colonized Mice.

Fig 6. Administration of a Four-Bacteria Consortium Clears VRE from Densely Colonized Mice.
  • Caballero S, Kim S, Carter RA, Leiner IM, Sušac B, Miller L, Kim GJ, Ling L, Pamer EG

  • Cell Host Microbe. 2017 May 10;21(5):592-602.e4

2017-06-08

Fig 3. The figure in Adobe Illustrator after expanding via Image Trace.

Fig 3. The figure in Adobe Illustrator after expanding via Image Trace.
  • Satagopan JM, Iasonos A, Kanik JG

  • Data Brief. 2017 May 5;12:667-675.
Open Access button

2017-06-09

Fig 3. Deuteration profile of myrMA at pH 7.4 (left) and pH 8.0 (right) after 30 min of incubation in D2O.

Fig 3. Deuteration profile of myrMA at pH 7.4 (left) and pH 8.0 (right) after 30 min of incubation in D2O.
  • Eells R, Barros M, Scott KM, Karageorgos I, Heinrich F, Lösche M

  • Biointerphases. 2017 May 16;12(2):02D408.
Open Access button

2017-06-12

Fig 1. Risk stratification for small nodules.

Fig 1. Risk stratification for small nodules.
  • Eguchi T, Adusumilli PS

  • J Thorac Cardiovasc Surg. 2017 Jun;153(6):1557-1562.

2017-06-13

Fig 1. Current strategies of gut microbiota modulation.

Fig 1. Current strategies of gut microbiota modulation.
  • Slingerland AE, Schwabkey Z, Wiesnoski DH, Jenq RR

  • Front Immunol. 2017 Apr 12;8:400.
Open Access button

2017-06-14

Fig 1. Expression of a deconjugation-resistant NEDD8 mutant (L73P) stabilizes neddylation of cullins and other non-cullin substrates.

Fig 1. Expression of a deconjugation-resistant NEDD8 mutant (L73P) stabilizes neddylation of cullins and other non-cullin substrates.
  • Coleman KE, Békés M, Chapman JR, Crist SB, Jones MJ, Ueberheide BM, Huang TT

  • Elife. 2017 May 5;6.
Open Access button

2017-06-15

Fig 1. Best response of target lesions (RECIST 1.1) in all patients with a radiographic assessment of response.

Fig 1. Best response of target lesions (RECIST 1.1) in all patients with a radiographic assessment of response.
  • Yu HA, Sima C, Feldman D, Liu LL, Vaitheesvaran B, Cross J, Rudin CM, Kris MG, Pao W, Michor F, Riely GJ

  • Ann Oncol. 2017 Feb 1;28(2):278-284.

2017-06-16

Fig 2. ChIP-Seq Experiments Reveal Distinct but Overlapping Patterns of H3K27 Acetylation on Asynchronous and Mitotic ESCs.

Fig 2. ChIP-Seq Experiments Reveal Distinct but Overlapping Patterns of H3K27 Acetylation on Asynchronous and Mitotic ESCs.
  • Liu Y, Pelham-Webb B, Di Giammartino DC, Li J, Kim D, Kita K, Saiz N, Garg V, Doane A, Giannakakou P, Hadjantonakis AK, Elemento O, Apostolou E

  • Cell Rep. 2017 May 16;19(7):1283-1293.
Open Access button

2017-06-19

Fig 1. Physical characterization of the surface-converting nanoparticles.

Fig 1. Physical characterization of the surface-converting nanoparticles.
  • Fay F, Hansen L, Hectors SJCG, Sanchez-Gaytan BL, Zhao Y, Tang J, Munitz J, Alaarg A, Braza MS, Gianella A, Aaronson SA, Reiner T, Kjems J, Langer R, Hoeben FJM, Janssen HM, Calcagno C, Strijkers GJ, Fayad ZA, Pérez-Medina C, Mulder WJM

  • Bioconjug Chem. 2017 May 17;28(5):1413-1421.

2017-06-20

Fig 1. BRD4 Silencing Enhances Autophagic Flux.

Fig 1. BRD4 Silencing Enhances Autophagic Flux.
  • Sakamaki JI, Wilkinson S, Hahn M, Tasdemir N, O’Prey J, Clark W, Hedley A, Nixon C, Long JS, New M, Van Acker T

  • Mol Cell. 2017 May 18;66(4):517-532.e9.
Open Access button

2017-06-21

Fig 3. Therapeutic T cell design: goals and strategies.

Fig 3. Therapeutic T cell design: goals and strategies.
  • Sadelain M, Rivière I, Riddell S

  • Nature. 2017 May 24;545(7655):423-431.

2017-06-22

Fig 3. ASXL2 target genes overlap with those of RUNX1 and AML1-ETO.

Fig 3. ASXL2 target genes overlap with those of RUNX1 and AML1-ETO.
  • Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang XJ, Yoshimi A

  • Nat Commun. 2017 May 18;8:15429.
Open Access button

2017-06-23

Fig 1. Infectious and noninfectious pulmonary complications of hematopoietic cell transplantation.

Fig 1. Infectious and noninfectious pulmonary complications of hematopoietic cell transplantation.
  • Harris B, Geyer AI

  • Clin Chest Med. 2017 Jun;38(2):317-331.

2017-06-26

Fig 2. The Siewert–Stein classification of gastroesophageal region cancers.

Fig 2. The Siewert–Stein classification of gastroesophageal region cancers.
  • Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S

  • Nat Rev Dis Primers. 2017 Jun 1;3:17036.

2017-06-28

Fig 1. VEOX decreased DNA methylation and induced reexpression of TSGs in tumor cells.

Fig 1. VEOX decreased DNA methylation and induced reexpression of TSGs in tumor cells.
  • Schneider BJ, Shah MA, Klute K, Ocean A, Popa E, Altorki N, Lieberman M, Schreiner A, Yantiss R, Christos PJ, Palmer R

  • Clin Cancer Res. 2017 Jun 1;23(11):2673-2680.

2017-06-29

Fig 8. Model for 6-ETI’s mechanism of action.

Fig 8. Model for 6-ETI’s mechanism of action.
  • Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D, Niesvizky R

  • J Clin Invest. 2017 Jun 1;127(6):2066-2080.

2017-06-30

Fig 2. Steady state plasma concentration of perifosine at weeks 2, 3, and 4.

Fig 2. Steady state plasma concentration of perifosine at weeks 2, 3, and 4.
  • Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, Kolesar JM, Huse JT, Kramer K, Cheung NV, Dunkel IJ

  • PLoS One. 2017 Jun 5;12(6):e0178593.
Open Access button